DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Switzerland
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
BANB logo

Bachem Holding AG Stock Price

SWX:BANB Community·CHF 5.8b Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 34 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

BANB Share Price Performance

CHF 77.45
15.05 (24.12%)
​
CHF 249.99
Fair Value
CHF 77.45
15.05 (24.12%)
69.0% undervalued intrinsic discount
CHF 249.99
Fair Value
Price CHF 77.45
Degen_GCR CHF 249.99
AnalystConsensusTarget CHF 81.40
AnalystHighTarget CHF 110.00
Sun, 26 Apr 26
Fair ValueCHF 249.99
Share Pricen/a

BANB Community Narratives

DE
Degen_GCR
Degen_GCR's
Fair Value
·
Fair Value CHF 249.99 69.0% undervalued intrinsic discount

Bachem Holding - The Purest Public Peptide Play?

1users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value CHF 81.4 4.9% undervalued intrinsic discount

Building K Production Will Serve Peptide And Oligonucleotide Therapies

0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value CHF 110 29.6% undervalued intrinsic discount

Expanding Facilities And Secular Trends Will Fuel Peptide Therapeutics Demand

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
BANB logo
Bachem Holding
69.0% undervalued intrinsic discount

Bachem Holding - The Purest Public Peptide Play?

View narrative
DE
Degen_GCR
Degen_GCR
Published 26 Apr
Read Narrative
BANB logo
Bachem Holding
47.8% overvalued intrinsic discount
Updated

Strict Global Regulation And Rising Costs Will Impede Peptide Capacity

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 7 Sep
Read Narrative
BANB logo
Bachem Holding
4.9% undervalued intrinsic discount

Building K Production Will Serve Peptide And Oligonucleotide Therapies

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 30 Jul
Read Narrative
BANB logo
Bachem Holding
29.6% undervalued intrinsic discount

Expanding Facilities And Secular Trends Will Fuel Peptide Therapeutics Demand

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 5 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

DE
Degen_GCR
BANB logo

Bachem Holding - The Purest Public Peptide Play?

Fair Value: CHF 249.99 69.0% undervalued intrinsic discount
10 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
BANB logo

BANB: New Manufacturing Partnership Will Raise Execution Risk And Limit Future Upside

Fair Value: CHF 52.4 47.8% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
BANB logo

BANB: Future Execution At New Facility Is Expected To Sustain Fair Value

Fair Value: CHF 81.4 4.9% undervalued intrinsic discount
11 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with proven track record.

0 Risks
3 Rewards
View Full Analysis

Bachem Holding AG Key Details

CHF 708.5m

Revenue

CHF 517.2m

Cost of Revenue

CHF 191.3m

Gross Profit

CHF 42.4m

Other Expenses

CHF 149.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Mar 04, 2027
1.99
27.00%
21.02%
14.4%
View Full Analysis

About BANB

Founded
1971
Employees
2725
CEO
Anne-Kathrin Stoller
WebsiteView website
www.bachem.com

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.

Recent BANB News & Updates

User avatar
Narrative Update • Sep 07

BANB: New Manufacturing Partnership Will Raise Execution Risk And Limit Future Upside

The analyst price target for Bachem Holding has been adjusted from CHF 50.36 to CHF 52.40. Analysts point to updated fair value estimates, a revised discount rate, and refreshed assumptions for revenue growth, profit margins, and future P/E as the key drivers behind this change.

Recent updates

No updates

Bachem Holding AG Competitors

LONN logo

Lonza Group

Symbol: SWX:LONN
Market cap: CHF 37.6b
GALD logo

Galderma Group

Symbol: SWX:GALD
Market cap: CHF 36.2b
SDZ logo

Sandoz Group

Symbol: SWX:SDZ
Market cap: CHF 29.3b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide